Emergent BioSolutions Inc (EBS) - Financial and Strategic SWOT Analysis Review
Emergent BioSolutions Inc (EBS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
Emergent BioSolutions Inc (Emergent) is a life sciences company that provides solutions to address public health threats including chemical, biological, radiological, nuclear and explosives (CBRNE), emerging infectious diseases, travel health, emerging health crises and acute/emergency care. It offers vaccines, therapeutics, drug-device combination products and contract development and manufacturing services. Emergent has a developmental pipeline of candidates targeting dengue and other influenza infections. It also offers its specialized products to governments and commercial customers. The company distributes its products in the US and Canada through its commercial sales forces and third-party distributors. Emergent is headquartered in Rockville, Maryland, the US.
Emergent BioSolutions Inc Key Recent Developments
Mar 02,2021: Biden’s latest announcement about invoking DPA
Feb 18,2021: Emergent BioSolutions Reports Financial Results for Fourth Quarter and Full Year 2020
Feb 04,2021: Emergent BioSolutions to release fourth quarter and full year 2020 financial results and conduct a conference call on february 18, 2021
Jan 12,2021: Department of Justice issues positive business review letter to companies developing plasma therapies for Covid-19
Jan 10,2021: Emergent BioSolutions announces 2021 financial guidance, provides preliminary 2020 results
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Emergent BioSolutions Inc (Emergent) is a life sciences company that provides solutions to address public health threats including chemical, biological, radiological, nuclear and explosives (CBRNE), emerging infectious diseases, travel health, emerging health crises and acute/emergency care. It offers vaccines, therapeutics, drug-device combination products and contract development and manufacturing services. Emergent has a developmental pipeline of candidates targeting dengue and other influenza infections. It also offers its specialized products to governments and commercial customers. The company distributes its products in the US and Canada through its commercial sales forces and third-party distributors. Emergent is headquartered in Rockville, Maryland, the US.
Emergent BioSolutions Inc Key Recent Developments
Mar 02,2021: Biden’s latest announcement about invoking DPA
Feb 18,2021: Emergent BioSolutions Reports Financial Results for Fourth Quarter and Full Year 2020
Feb 04,2021: Emergent BioSolutions to release fourth quarter and full year 2020 financial results and conduct a conference call on february 18, 2021
Jan 12,2021: Department of Justice issues positive business review letter to companies developing plasma therapies for Covid-19
Jan 10,2021: Emergent BioSolutions announces 2021 financial guidance, provides preliminary 2020 results
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
SECTION 1 - ABOUT THE COMPANY
Emergent BioSolutions Inc - Key Facts
Emergent BioSolutions Inc - Key Employees
Emergent BioSolutions Inc - Key Employee Biographies
Emergent BioSolutions Inc - Major Products and Services
Emergent BioSolutions Inc - History
Emergent BioSolutions Inc - Company Statement
Emergent BioSolutions Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture
SECTION 2 – COMPANY ANALYSIS
Company Overview
Emergent BioSolutions Inc - Business Description
Business Segment: Contract Development and Manufacturing Services
Performance
Business Segment: Contracts and Grants
Performance
Business Segment: Product Sales
Performance
Emergent BioSolutions Inc - Corporate Strategy
Emergent BioSolutions Inc - SWOT Analysis
SWOT Analysis - Overview
Emergent BioSolutions Inc - Strengths
Emergent BioSolutions Inc - Weaknesses
Emergent BioSolutions Inc - Opportunities
Emergent BioSolutions Inc - Threats
Emergent BioSolutions Inc - Key Competitors
SECTION 3 – COMPANY FINANCIAL RATIOS
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES
Emergent BioSolutions Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Emergent BioSolutions Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Emergent BioSolutions Inc, Recent Deals Summary
SECTION 5 – COMPANY’S RECENT DEVELOPMENTS
Mar 02, 2021: Biden’s latest announcement about invoking DPA
Feb 18, 2021: Emergent BioSolutions Reports Financial Results for Fourth Quarter and Full Year 2020
Feb 04, 2021: Emergent BioSolutions to release fourth quarter and full year 2020 financial results and conduct a conference call on february 18, 2021
Jan 12, 2021: Department of Justice issues positive business review letter to companies developing plasma therapies for Covid-19
Jan 10, 2021: Emergent BioSolutions announces 2021 financial guidance, provides preliminary 2020 results
Nov 05, 2020: Emergent BioSolutions reports financial results for third quarter and nine months ended September 30, 2020 and updates full year 2020 guidance
Sep 24, 2020: Emergent BioSolutions applauds Pharmacy Leaders on Consensus Guidelines for Naloxone
Aug 31, 2020: Emergent BioSolutions teams up with Boston Red Sox, Cincinnati Reds, Philadelphia Phillies, and MAPDA to highlight importance of overdose reversal medicines on International Overdose Awareness Day
Aug 26, 2020: Emergent BioSolutions announces appointment of Marvin White to the Company’s Board of Directors
Jul 30, 2020: Emergent BioSolutions reports financial results for second quarter and six months ended june 30, 2020 and revises upward full year 2020 guidance
SECTION 6 – APPENDIX
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
Emergent BioSolutions Inc - Key Facts
Emergent BioSolutions Inc - Key Employees
Emergent BioSolutions Inc - Key Employee Biographies
Emergent BioSolutions Inc - Major Products and Services
Emergent BioSolutions Inc - History
Emergent BioSolutions Inc - Company Statement
Emergent BioSolutions Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture
SECTION 2 – COMPANY ANALYSIS
Company Overview
Emergent BioSolutions Inc - Business Description
Business Segment: Contract Development and Manufacturing Services
Performance
Business Segment: Contracts and Grants
Performance
Business Segment: Product Sales
Performance
Emergent BioSolutions Inc - Corporate Strategy
Emergent BioSolutions Inc - SWOT Analysis
SWOT Analysis - Overview
Emergent BioSolutions Inc - Strengths
Emergent BioSolutions Inc - Weaknesses
Emergent BioSolutions Inc - Opportunities
Emergent BioSolutions Inc - Threats
Emergent BioSolutions Inc - Key Competitors
SECTION 3 – COMPANY FINANCIAL RATIOS
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES
Emergent BioSolutions Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Emergent BioSolutions Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Emergent BioSolutions Inc, Recent Deals Summary
SECTION 5 – COMPANY’S RECENT DEVELOPMENTS
Mar 02, 2021: Biden’s latest announcement about invoking DPA
Feb 18, 2021: Emergent BioSolutions Reports Financial Results for Fourth Quarter and Full Year 2020
Feb 04, 2021: Emergent BioSolutions to release fourth quarter and full year 2020 financial results and conduct a conference call on february 18, 2021
Jan 12, 2021: Department of Justice issues positive business review letter to companies developing plasma therapies for Covid-19
Jan 10, 2021: Emergent BioSolutions announces 2021 financial guidance, provides preliminary 2020 results
Nov 05, 2020: Emergent BioSolutions reports financial results for third quarter and nine months ended September 30, 2020 and updates full year 2020 guidance
Sep 24, 2020: Emergent BioSolutions applauds Pharmacy Leaders on Consensus Guidelines for Naloxone
Aug 31, 2020: Emergent BioSolutions teams up with Boston Red Sox, Cincinnati Reds, Philadelphia Phillies, and MAPDA to highlight importance of overdose reversal medicines on International Overdose Awareness Day
Aug 26, 2020: Emergent BioSolutions announces appointment of Marvin White to the Company’s Board of Directors
Jul 30, 2020: Emergent BioSolutions reports financial results for second quarter and six months ended june 30, 2020 and revises upward full year 2020 guidance
SECTION 6 – APPENDIX
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
LIST OF TABLES
Emergent BioSolutions Inc, Key Facts
Emergent BioSolutions Inc, Key Employees
Emergent BioSolutions Inc, Key Employee Biographies
Emergent BioSolutions Inc, Major Products and Services
Emergent BioSolutions Inc, History
Emergent BioSolutions Inc, Other Locations
Emergent BioSolutions Inc, Subsidiaries
Emergent BioSolutions Inc, Joint Venture
Emergent BioSolutions Inc, Key Competitors
Emergent BioSolutions Inc, Ratios based on current share price
Emergent BioSolutions Inc, Annual Ratios
Emergent BioSolutions Inc, Annual Ratios (Cont...1)
Emergent BioSolutions Inc, Annual Ratios (Cont...2)
Emergent BioSolutions Inc, Interim Ratios
Emergent BioSolutions Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Emergent BioSolutions Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Emergent BioSolutions Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
Emergent BioSolutions Inc, Key Facts
Emergent BioSolutions Inc, Key Employees
Emergent BioSolutions Inc, Key Employee Biographies
Emergent BioSolutions Inc, Major Products and Services
Emergent BioSolutions Inc, History
Emergent BioSolutions Inc, Other Locations
Emergent BioSolutions Inc, Subsidiaries
Emergent BioSolutions Inc, Joint Venture
Emergent BioSolutions Inc, Key Competitors
Emergent BioSolutions Inc, Ratios based on current share price
Emergent BioSolutions Inc, Annual Ratios
Emergent BioSolutions Inc, Annual Ratios (Cont...1)
Emergent BioSolutions Inc, Annual Ratios (Cont...2)
Emergent BioSolutions Inc, Interim Ratios
Emergent BioSolutions Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Emergent BioSolutions Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Emergent BioSolutions Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
LIST OF FIGURES
Emergent BioSolutions Inc, Performance Chart (2016 - 2020)
Emergent BioSolutions Inc, Ratio Charts
Emergent BioSolutions Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Emergent BioSolutions Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021
Emergent BioSolutions Inc, Performance Chart (2016 - 2020)
Emergent BioSolutions Inc, Ratio Charts
Emergent BioSolutions Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Emergent BioSolutions Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021